The source discusses research indicating that postmenopausal women on hormone therapy (HT) experience significantly greater weight loss when treated with tirzepatide, an obesity medication, compared to those not on HT. This effect mirrors prior findings with semaglutide, another weight-loss drug, suggesting a synergistic interaction where HT enhances the efficacy of these medications in this demographic. The study, presented at ENDO 2025, observed that HT users achieved weight loss comparable to younger, non-menopausal individuals, while non-HT users saw more modest results, implying that menopause may impair the response to anti-obesity drugs without HT. Researchers hypothesize that estrogen’s positive influence on metabolism and GLP-1 signaling contributes to this enhanced weight loss, though individual assessment of HT risks remains crucial.
Audio Overview (Google NotebookLM)
(20 minutes 30 seconds)
